Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 29, 2024 07:46 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 29, 2024 07:45 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024 07:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 07, 2024 07:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024 16:40 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
November 14, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S....
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 03, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter...
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
October 24, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
October 03, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A...
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
September 22, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in...